Clinical trials: Pemphigus Disease

Pemphigus Vulgaris

Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

• Terminated
• Age: 18 to 70 years
• Phase 3
• Injection or infusion
• Results posted

Pemphigus vulgaris (PV) is a rare, chronic, debilitating, and potentially life-threatening autoimmune disorder that is characterized by mucocutaneous blisters.

Trial name

NCT01920477

Testing

Ofatumumab

Where

16 sites in United States, Australia and 6 more

Volunteers

35 people

Sponsor

Novartis Pharmaceuticals